ClinicalTrials.gg
CompletedNCT05794477Updated Nov 13, 2026

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of Adebrelimab and SHR-1802 in Advanced Solid Tumor, sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1/2, Interventional, and Treatment

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of SHR-1802 combined with adebrelimab in patients with advanced solid tumors, determine the RP2D of SHR-1802 combined with adebrelimab ± chemotherapy, and evaluate the efficacy of SHR-1802 combined with adebrelimab ± chemotherapy in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd. is the lead sponsor of 61 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written ;
  2. (ECOG) performance status of 0-1;
  3. Has a ≥ 12 weeks;
  4. At least one according to v1.1;
  5. confirmed advanced solid tumor;
  6. Adequate bone marrow reserve and organ function.

Exclusion criteria

Exclusion Criteria:

  1. Have received or PD-L1 antibody therapy;
  2. Subjects with other malignant tumors in the past 3 years;
  3. Have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites;
  4. Previous or current interstitial pneumonia/interstitial lung disease ;
  5. History of disease with the possibility of recurrence or active autoimmune disease;
  6. Severe infection within 1 month before the first study drug administration;
  7. The presence of other serious physical or mental disorders or abnormalities in laboratory tests that may increase the risk of study participation or interfere with study results, as well as patients deemed unsuitable for study participation by the investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    phase Ib:SHR-1802+Adebrelimab

    Biological: Adebrelimab · Biological: SHR-1802

  • Experimental
    phase II cohort 1: SHR-1802+Adebrelimab

    Biological: Adebrelimab · Biological: SHR-1802

  • Experimental
    phase II cohort 2: SHR-1802+Adebrelimab + Platinum Doublet Chemotherapy (PDCT)

    Biological: Adebrelimab · Biological: SHR-1802 · Drug: Carboplatin/Cisplatin · Drug: Paclitaxel/Nab-Paclitaxel/Pemetrexed

  • Experimental
    phase II cohort 3: SHR-1802+Adebrelimab + PDCT

    Biological: Adebrelimab · Biological: SHR-1802 · Drug: Carboplatin/Cisplatin · Drug: Paclitaxel/Nab-Paclitaxel/Pemetrexed

  • Experimental
    phase II cohort 4: SHR-1802+Adebrelimab

    Biological: Adebrelimab · Biological: SHR-1802

Interventions

  • BiologicalAdebrelimab

    Specified dose on specified days

  • BiologicalSHR-1802

    Specified dose on specified days

  • DrugCarboplatin/Cisplatin

    Drug pages: Carboplatin · Cisplatin

    Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

  • DrugPaclitaxel/Nab-Paclitaxel/Pemetrexed

    Drug pages: Albumin-Bound Paclitaxel · Pemetrexed

    Specified dose on specified days. Participant will receive only two of the listed chemotherapies (carboplatin, cisplatin, paclitaxel, nab-paclitaxel) along with immunotherapy.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)

    Time frame: 3 weeks

  2. Recommended phase II dose (RP2D)

    Time frame: up to 2 months

  3. ORR

    Objective Response Rate, determined according to RECIST v1.1 criteria

    Time frame: up to 2 years

Secondary outcomes

  1. DOR

    Duration of Response, determined according to RECIST v1.1 criteria

    Time frame: up to 2 years

  2. DCR

    Disease Control Rate, determined according to RECIST v1.1 criteria

    Time frame: up to 2 years

  3. PFS assessed by investigator

    Progression Free Survival, determined according to RECIST v1.1 criteria

    Time frame: up to 2 years

  4. TTR

    Time to Response,determined according to RECIST v1.1 criteria

    Time frame: up to 2 years

  5. OS (overall survival)

    From date of treatment start to any cause death or last follow-up

    Time frame: up to 2 years

  6. 12-month OS rate

    Time frame: from the date of the first dose up to 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Apr 2023 to primary completion in Aug 2024, 15 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jul 2025 → Aug 2024 and completion Dec 2025 → Aug 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Apr 3, 2023
StartActual
Apr 28, 2023
Primary completionActual
Aug 20, 2024was Jul 2025
CompletionActual
Aug 20, 2024was Dec 2025
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Jul 1, 2025→Aug 20, 2024 (actual)
Nov 13, 2026
Study completion
Dec 31, 2025→Aug 20, 2024 (actual)
Nov 13, 2026
Enrollment
132 (estimated)→16 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Jul 1, 2025→Aug 20, 2024 (now actual)
    Study completion Dec 31, 2025→Aug 20, 2024 (now actual)
    Enrollment 132 (estimated)→16 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05794477
Responsible party
Sponsor
First posted
Apr 3, 2023
Start date
Apr 28, 2023
Primary completion
Aug 20, 2024
Completion
Aug 20, 2024
Last update
Nov 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adebrelimab

Start the discussion